NASDAQ · URGN
Healthcare · Biotechnology
$46.86
Up+$0.06 (+0.13%)
Updated Aug 22, 2026, 12:48 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
URGN closed at $46.86 after 21 trading sessions, up 14.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $47.13 | $47.28 | $45.60 | $46.86 | 755.58K |
| Aug 20, 2026 | $49.71 | $49.71 | $46.20 | $46.80 | 1.12M |
| Aug 19, 2026 | $49.89 | $50.81 | $48.55 | $50.29 | 2.39M |
| Aug 18, 2026 | $48.93 | $49.5599 | $48.41 | $48.92 | 823.74K |
| Aug 17, 2026 | $48.51 | $49.5099 | $48.16 | $49.14 | 1.3M |
| Aug 14, 2026 | $47.68 | $48.48 | $46.62 | $48.22 | 458.06K |
| Aug 13, 2026 | $49.60 | $49.60 | $47.67 | $48.12 | 859.98K |
| Aug 12, 2026 | $47.49 | $49.67 | $47.12 | $49.00 | 1.58M |
| Aug 11, 2026 | $45.61 | $47.33 | $45.52 | $47.11 | 876.58K |
| Aug 10, 2026 | $46.74 | $46.8888 | $45.34 | $46.31 | 644.59K |
| Aug 7, 2026 | $47.23 | $48.19 | $45.75 | $46.96 | 1.03M |
| Aug 6, 2026 | $46.14 | $48.03 | $45.51 | $45.60 | 1.22M |
| Aug 5, 2026 | $42.17 | $47.84 | $40.4101 | $46.43 | 2.48M |
| Aug 4, 2026 | $39.29 | $40.46 | $38.805 | $39.92 | 734.55K |
| Aug 3, 2026 | $37.71 | $39.41 | $36.68 | $38.59 | 964.79K |
| Jul 31, 2026 | $41.10 | $41.105 | $38.01 | $38.24 | 814.72K |
| Jul 30, 2026 | $40.32 | $41.605 | $40.32 | $41.09 | 778.78K |
| Jul 29, 2026 | $41.10 | $41.50 | $40.04 | $40.45 | 317.82K |
| Jul 28, 2026 | $41.45 | $42.15 | $40.21 | $40.88 | 390.95K |
| Jul 27, 2026 | $41.05 | $41.9594 | $40.10 | $41.46 | 517.13K |
| Jul 24, 2026 | $42.52 | $42.89 | $40.78 | $40.97 | 421.33K |
The latest Smart Investors Daily articles mentioning URGN.
URGN research
Company profile and research snapshot.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 5, 2026 | TD Cowen | Buy | — |
| Jul 21, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Oppenheimer | Outperformer | — |
No generated briefing is available yet.
Benzinga · Aug 17, 2026
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application
Benzinga · Aug 6, 2026
Guggenheim analyst Michael Schmitz maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $42 to $58.
Benzinga · Aug 6, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $45 to $75.
Benzinga · Aug 5, 2026
TD Cowen analyst Tara Bancroft maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $50 to $60.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning URGN.
